Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment
Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment
Global Healthcare
In the journey of treating hematologic malignancies, for patients in advanced stages with no standard clinical treatment options, seeking medical care abroad or through remote video consultations has become a pathway to new hope. Through these means, patients can connect with top international experts and gain access to new treatment plans and more options. Leading international specialists not only continuously achieve breakthroughs in treatment technologies but also provide personalized treatment recommendations based on the latest research. Next, we are proud to introduce a highly acclaimed and renowned expert in the fields of hematology and lymphoma from China—Professor Ke Xiaoyan.
### Expert Profile
**Professor Ke Xiaoyan** is the Chief Physician of the Hematology Department at Peking University Third Hospital and serves as the Lead Expert of the Adult Lymphoma Division at the GoBroad Medical (Hematology) Beijing Research Center. She is also the Deputy Director of the Hematology Department at Peking University Health Science Center. Additionally, she holds the position of Chief Consultant for the Adult Lymphoma Department at Beijing GoBroad-Boren Hospital, where she has trained numerous PhD students, establishing herself as one of China’s top experts in hematologic oncology.
Professor Ke is highly regarded within the Chinese medical community. She has served as the Chairperson of the Hematology Branch of the Chinese Female Physicians Association and currently holds key positions in several authoritative medical organizations. Her academic background and international reputation have earned her wide recognition in the field of hematologic malignancy treatment.
### Areas of Expertise
Professor Ke has extensive experience in the standardized treatment of lymphoma, targeted chemotherapy, and both autologous and allogeneic hematopoietic stem cell transplantation. She is at the forefront of international research in treating relapsed and refractory lymphomas through second-generation gene sequencing, targeted therapies, and CAR-T cell immunotherapy. Beyond her clinical expertise, she is a leading figure in the molecular diagnosis of malignant blood diseases and the monitoring of minimal residual disease.
### Research Contributions and International Reputation
Professor Ke has made remarkable achievements in scientific research as well. She has been the principal investigator in more than 70 international multicenter clinical trials and has published over 300 academic papers, including more than 30 influential SCI papers in top-tier international journals, focusing on cutting-edge research in lymphoma and hematologic malignancies. She has authored and contributed to more than 30 authoritative medical books and received over 40 national research grants, significantly advancing the field of hematology.
In addition to her research work, Professor Ke serves on the editorial boards of several medical journals, including as Deputy Editor-in-Chief of the **Journal of Leukemia & Lymphoma**. She is also a consulting expert for the Ministry of Health and a key member of the Central Health Consultation Committee. As a leading figure in international hematologic oncology research, her studies encompass the molecular mechanisms of lymphoma, immunotherapy, and stem cell transplantation, enhancing China’s standing in global academic research.
### Main Research Focuses
– Standardized treatment of lymphoma
– Molecular diagnosis of malignant blood diseases and monitoring of minimal residual disease
– Research on autologous peripheral blood stem cell transplantation for malignant blood diseases
– Non-myeloablative transplantation and CAR-T cell therapy for refractory relapsed malignant lymphoma
– Research on B7/CD28 signaling and T-cell immune tolerance mechanisms
– Study of the molecular mechanisms of tumor immunity
### Publications and Research Achievements
Professor Ke Xiaoyan has authored several authoritative books in the field of lymphoma, including **Lymphoma** and **Lymphoma Diagnosis and Treatment Manual**. Her key SCI papers include:
-
**Biological and Clinical Influences of NPM1 in AML Patients with DNMT3A Mutations**, *Cancer Management and Research*, 2018.
-
**Clinical and Biological Implications of IDH1/2 in AML with DNMT3A Mutation**, *Cancer Management and Research*, 2018.
-
**High PD-L1 Expression Predicts Poor Prognosis in Diffuse Large B-cell Lymphoma**, *Annals of Hematology*, 2018.
-
**Molecular Predictors of Post-transplant Survival in Acute Myeloid Leukemia**, *Blood Cancer Journal*, 2017.
-
**High Expression of CPNE3 Predicts Adverse Prognosis in AML**, *Cancer Science*, 2017.
-
**High Expression of ETS2 Predicts Poor Prognosis in AML**, *Journal of Translational Medicine*, 2017.
-
**A Minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 Contributes to Leukemogenesis in t(8;21) AML**, *International Journal of Cancer*, 2017.